The size of the Therapeutic Vaccines Market in MEA was calculated at USD 314.95 Million in 2022. It is forecasted to grow USD 1504.00 Million by 2027, growing at a CAGR of 36.71% from 2022 to 2027.
Therapeutic vaccinations have grown in popularity as the prevalence of illnesses like cancer and HIV has increased. Technological advancements in HIV detection and expanded clinical trials for HIV and cancer vaccines are two important drivers driving the growth of the MEA therapeutic vaccines market. Furthermore, greater public awareness of critical illnesses and increased R&D spending on therapeutic vaccines boost the market for therapeutic vaccines.
Increased government funding for vaccine development, increased investments by leading market players, growing disease incidence, technical improvements, and NGOs' activities are some of the reasons driving the market forward.
The MEA market for therapeutic vaccines has been greatly influenced by the increasing prevalence of different chronic illnesses such as cancer, HIV, and cardiovascular disorders. Although these developments are still in the works and have yet to be commercialized, they suggest a new market potential for MEA therapeutic vaccines. In addition, malignancies caused by the human papillomavirus provide a potential opportunity for the MEA therapeutic vaccines market.
Massive capital expenditures, strict regulatory restrictions, and expensive treatment costs are a few reasons limiting the market's growth. Higher vaccination prices and a lack of therapeutic medication availability are limiting the MEA therapeutic vaccines industry. Furthermore, tight regulatory criteria for therapeutic vaccine approval impeded the MEA global therapeutic vaccines market. Ineffective research and development policies, as well as reimbursement regulations, are limiting the market.
The rise of the MEA therapeutic vaccines industry may be threatened by adverse side effects of therapeutic vaccination and a lack of understanding. In addition, issues such as the expensive cost of producing therapeutic vaccines will stifle market expansion.
Vaccine research and development, like medicine development, takes a long time and a lot of money. Before a vaccine can be commercially released, clinical trials must be completed. Unfortunately, many vaccines fail to succeed during these trials.
This research report on the Middle-East & Africa therapeutic vaccines market has been segmented and sub-segmented into the following categories:
By Disease Type:
Several governments and humanitarian groups have taken initiatives to prevent diseases and vaccinate as many children and adults as possible, which led to a change in production and supply strategies and a rise in the donor market, the biggest market for vaccines.
Following the Middle East, Africa has the largest market share for MEA therapeutic vaccines. Africa has a significant HIV/AIDS epidemic, as well as a high AIDS rate. Despite having just 15.2 percent of the world's population, Africa accounts for over 70% of all AIDS-related fatalities and 69% of all HIV-related deaths. In South Africa, a clinical experiment for Aids therapy has yielded promising findings. HIV patients with the HIV vaccine have a more robust immune system, making antiviral drugs more effective. With an AIDS-infected population in the African subcontinent, this probably indicates an increase in therapeutic vaccines. This, coupled with the Middle East economies' spending power and their recently booming markets, makes this region a lucrative one for market players.
KEY MARKET PLAYERS:
Some of the prominent companies leading the Middle-East & Africa Therapeutic Vaccines Market profiled in the report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
18.104.22.168 PR1 Peptide
5.1.3 Neurological Disease Vaccines
22.214.171.124 ACC- 001
126.96.36.199 CAD 106
188.8.131.52 Parkinson's Disease Vaccine
184.108.40.206 Alzheimer's Disease
5.1.4 Infectious Disease Vaccines
220.127.116.11 Hepatitis C
18.104.22.168 Other Infectious Disease
6. Geographical Analysis
6.2 Middle East
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GlaxoSMithKline plc.
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.